The government of Kenya has launched a two-phase integrated measles vaccination campaign, targeting more than five million children aged between nine months and five years. In addition to measles vaccinations, the campaign will provide other life-saving health interventions, including polio vaccinations (in select districts), vitamin A and de-worming medicine. Residents in the Nyanza and Western provinces will also receive insecticide-treated nets, proven to be one of the most effective and cost-efficient means of preventing malaria.
The campaign is being supported by the Measles Initiative, a partnership formed to reduce measles deaths in sub-Saharan Africa, which is led by the American Red Cross, United Nations Foundation, World Health Organization, United Nations Children's Fund (UNICEF) and US Centers for Disease Control and Prevention (CDC). In addition, the Global Fund to Fight AIDS, Tuberculosis, and Malaria has provided long-lasting insecticide treated nets to combat malaria, which is a leading cause of childhood death and disability in Kenya as in many other African countries. The Kenya Red Cross Society will be working with the government and other partners to educate and mobilize communities.
"The Kenya campaign was accelerated to protect children from a recent measles outbreak, the re-emergence of polio in Somalia and the effects of a severe drought," said Per Engeback, UNICEF Regional Director for East and Southern Africa. "The drought led to a food crisis that increased malnutrition in children, making them even more susceptible to measles," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze